Novavax, Inc (NASDAQ:NVAX) has a beta value of 2.12 and has seen 3.14 million shares traded in the last trading session. The company, currently valued at $1.58B, closed the last trade at $9.87 per share which meant it lost -$0.95 on the day or -8.78% during that session. The NVAX stock price is -141.74% off its 52-week high price of $23.86 and 64.24% above the 52-week low of $3.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.55 million shares traded. The 3-month trading volume is 5.25 million shares.
The consensus among analysts is that Novavax, Inc (NVAX) is Buy stock at the moment, with a recommendation rating of 2.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 16 have rated it as a Hold, with 10 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.65.
Novavax, Inc (NASDAQ:NVAX) trade information
Sporting -8.78% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NVAX stock price touched $9.87 or saw a rise of 14.55%. Year-to-date, Novavax, Inc shares have moved 22.76%, while the 5-day performance has seen it change 22.76%. Over the past 30 days, the shares of Novavax, Inc (NASDAQ:NVAX) have changed 10.40%. Short interest in the company has seen 39.16 million shares shorted with days to cover at 8.74.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 55.14% from current levels. The projected low price target is $14.0 while the price target rests at a high of $25.0. In that case, then, we find that the current price level is -153.29% off the targeted high while a plunge would see the stock gain -41.84% from current levels.
Novavax, Inc (NVAX) estimates and forecasts
Figures show that Novavax, Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -17.34% over the past 6 months, with this year growth rate of 73.38%, compared to 17.00% for the industry. Revenue growth from the last financial year stood is estimated to be -26.39%.
4 analysts offering their estimates for the company have set an average revenue estimate of 90.92M for the current quarter. 1 have an estimated revenue figure of 47.5M for the next ending quarter. Year-ago sales stood 291.34M and 93.86M respectively for this quarter and the next, and analysts expect sales will shrink by -68.79% for the current quarter and -26.39% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.55% over the past 5 years. Earnings growth for 2025 is a modest 76.43% while over the next 5 years, the company’s earnings are expected to increase by 37.90%.
NVAX Dividends
Novavax, Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Novavax, Inc (NASDAQ:NVAX)’s Major holders
Insiders own 4.41% of the company shares, while shares held by institutions stand at 59.98% with a share float percentage of 62.75%. Investors are also buoyed by the number of investors in a company, with Novavax, Inc having a total of 322.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 14.08 million shares worth more than $178.19 million. As of 2024-06-30, VANGUARD GROUP INC held 10.0599% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 11.85 million shares as of 2024-06-30. The firm’s total holdings are worth over $149.98 million and represent 8.4669% of shares outstanding.
